The 2026 Crohn’s & Colitis Congress recently concluded in Las Vegas, Nevada. The annual congress represents a partnership between the Crohn’s & Colitis Foundation and the American Gastroenterological Association (AGA). The 2026 Crohn’s & Colitis Congress ran from January 22 through January 24 and featured three days of networking, collaboration, and exploration of the latest in IBD management and care.
Today, we are taking a look at some of the abstracts that were presented at the congress, along with the abstracts that took home awards, and a quick look at what CME credits are available for individuals who attended or for those gauging interest in next year’s event.
2026 Crohn’s & Colitis Congress Abstracts
The following are a curated selection of abstracts presented at the 2026 Crohn’s & Colitis Congress. A complete list of Crohn’s & Colitis Congress abstracts are available in the February 2026 supplement of Gastroenterology. The complete abstracts are restricted to subscribers or buyers. Some descriptions and conclusions were edited for brevity and clarity.
- A Subset of Algorithmic Biomarkers Derived Using Quantitative AI Based on Evolutionary Computation That Predict TNF Response in Rheumatoid Arthritis Also Have 100% Accuracy Predicting TNF Response in Ulcerative Colitis, Crohn's Ileitis and Crohn's Colitis
- Description: [Researchers] hypothesized that algorithmic gene expression biomarkers, highly predictive of individual responses to TNF therapy in rheumatoid arthritis (RA), would also enable derivation of algorithmic biomarkers predictive of individual responses to TNF therapy in both ulcerative colitis (UC) and Crohn’s disease (CD).
- Comparative Outcomes After Index Myocardial Infarction in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
- Description: While prior studies have linked IBD to increased risk of myocardial infarction (MI), post-MI outcomes in this population remain poorly characterized. [The researchers] aimed to evaluate post-MI outcomes in patients with IBD compared to non-IBD controls.
- Impact of Anti-Inflammatory Diet Versus High-Fiber Diet on Symptomatic Remission and Fecal Calprotectin in Inflammatory Bowel Disease
- Description: The UCLA anti-inflammatory diet (AID) was developed by gastroenterology-specialized dietitians after a comprehensive review of anti-inflammatory nutrients in the research literature. The aim of this study was to compare the effectiveness of AID versus high-fiber diet in patients with IBD.
- Early Proactive Therapeutic Drug Monitoring of Infliximab Accelerates Time to Remission in Children with Inflammatory Bowel Disease
- Description: Existing literature suggests that optimizing IFX dosing in response to levels at week 14, prior to the start of maintenance infusions, offers clinical benefit at 52 weeks. There has been growing interest in beginning proactive TDM earlier, prior to the 3rd and final induction infusion. We hypothesize that early proactive TDM prior to the 3rd versus 4th IFX infusion improves clinical outcomes in children with IBD.
2026 Early Career Investigator Abstract Awards
The 2026 Crohn’s & Colitis Congress awarded five Early Career Investigator Abstract Awards to the following early career researchers who are within a half-decade of completing their training or are currently in training.
- Bianca Islam, MD, PhD for Repositioning Dual Glp-1/Gip Receptor Agonists for the Treatment of Colitis and Colitis-Associated Tumorigenesis
- Ji Yeon Kim, PhD for Indole Acetic Acid as an Inhibitor of Myeloperoxidase-Mediated Bystander Tissue Damage in Inflammatory Bowel Disease
- Erifili Lianopoulou, MSc for CD8+ T-Cells Define Sex-Specific Responses to IL-23 Treatment in CD
- Marina Macchi, MD for Quantitative Small Bowel Motility Assessment on Magnetic Resonance Enterography in Pediatric Crohn Disease: Associations with Clinical Phenotype and Surgical Outcome
- Alfredo Ornelas, Ph.D. for Metabolite Mimicry Reveals Butyrate Analog with Selective Protective Functions in the Intestinal Mucosa
A complete list of Crohn’s & Colitis Congress abstracts are available in the February 2026 supplement of Gastroenterology.
Crohn’s & Colitis Congress Continuing Education
Physicians, pharmacists, pharmacy technicians, nurses, and physician assistants are all in scope to receive credit for their attendance. Providers can claim up to 17.75 credit hours, where appropriate.
Additionally, 17.75 hours are available for the American Board of Internal Medicine's Maintenance of Certification program and for the American Board of Pediatrics’ Maintenance of Certification program.
Although the opportunity to attend this year’s congress has passed, prospective attendees can anticipate a similar level of credit availability for next year’s congress, which is also scheduled to be three days long. The 2027 Crohn’s & Colitis Congress is currently set for January 21 through January 23, in New Orleans, Louisiana.
Sign up for alerts and stay informed on the latest published guidelines and articles.
Copyright © 2026 Guideline Central, all rights reserved.